1[1]Kerr, R, Stiring D, Ludlam CA. Interleukin 6 and haemostasis[J].BrJ Haematol, 2001, 115(1) :3 ～12.
2[2]Bernardo A, Ball C, Dong JF, et al. Effect of inflammatory cytokines on the release and cleavage of the endothelial cell-drived ultralarge von Will ebrand factor multimers under flow[J]. Blood, 2004,104(1) :100～106.
3[3]van Aken BE. Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis:evidence for a role of inflammation in thrombosis [J]. BrJ Haematol, 2002, 116(1): 173 ～177.
4[4]Dugina TN, Kiseleva EV, Strukova SM, et al. Receptors of the PAR family as link between blood coagulation and inflammation[J].Biochemistry, 2002, 67 (1) :65 ～ 74.
5[5]Campbell WD, Lazoura E, Okada H,et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N [J]. Microbol Immunol, 2002, 46(2) :131 ～134.
6[6]Myers DD, Chapman AM, Wakefield TW, et al. Cellular IL-10 is more effetrive than viral IL-10 in decreasing venous thrombosis[J]. J Surg Res, 2003, 112(2) :168 ～ 174.
7[7]Prager GW, Breuss JM, Binder BR, et al. Vascular endothelial groth factor(VEGF) induces rapid prourokinase (pro-uPA) activation on surface of endothelial cell[J]. Blood, 2004, 103 (3) :955 ～962.
8[8]Cacciola RR, di Franceso ED, Cacciola E, et al. Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications [J]. Haematologica, 2002, 87(7) :774 ～775.
9[9]Blamn AD, Belgore FM, Lip GY, et al. Plasma vescular endothelial growth factor and is receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate [J].Am J Cardiol,2001,87(10) :1160 ～1163.
10[10]Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer[J]. 2003,124 (3 Suppl) :58 s ～ 68 s.
10Min JK, Kim YM, Kim SW, et al. TNF-related activationinduced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptorassociated factor and protein kinase C-dependent NF- kappaB activation in endothelial cells [J]. J Immunol, 2005, 175(1): 531-540.
